共 355 条
[1]
Ansaripour A(2016)Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran J Cancer Policy. 9 8-13
[2]
Uyl-de Groot CA(2013)6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Lancet Oncol 14 741-748
[3]
Foroozanfar M(2013)2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet. 382 1021-1028
[4]
Rahimimoghadam S(2016)Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran Value Health. 19 A355-650
[5]
Redekop WK(2012)Age at diagnosis and breast cancer survival in Iran Int J Breast Cancer. 2012 517976-5528
[6]
Pivot X(2011)Prevalence of breast cancer in a defined population of Iran Iran Red Crescent Med J. 13 647-432
[7]
Romieu G(2012)Standardized breast cancer mortality rate compared to the general female population of Iran Asian Pacific J Cancer Prev. 13 5525-36
[8]
Debled M(2011)Updated Cost-effectiveness analysis of trastuzumab for early breast cancer PharmacoEconomics. 29 415-244
[9]
Pierga J(2007)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet. 369 29-1998
[10]
Kerbrat P(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-391